Last update 03 Apr 2025

Sebelipase Alfa

Overview

Basic Info

Drug Type
Enzyme
Synonyms
Lysosomal acid lipase, Recombinant human lysosomal acid lipase, Recombinant lysosomal acid lipase
+ [9]
Target
Action
modulators
Mechanism
LIPA modulators(lipase A, lysosomal acid type modulators)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
European Union (28 Aug 2015),
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cholesterol Ester Storage Disease
United Kingdom
31 Jan 2016
Wolman Disease
European Union
28 Aug 2015
Wolman Disease
Iceland
28 Aug 2015
Wolman Disease
Liechtenstein
28 Aug 2015
Wolman Disease
Norway
28 Aug 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Failure to ThrivePhase 3
United States
04 May 2011
Failure to ThrivePhase 3
Egypt
04 May 2011
Failure to ThrivePhase 3
France
04 May 2011
Failure to ThrivePhase 3
Ireland
04 May 2011
Failure to ThrivePhase 3
United Kingdom
04 May 2011
Gilbert DiseasePhase 2
United States
12 Dec 2011
Gilbert DiseasePhase 2
Canada
12 Dec 2011
Gilbert DiseasePhase 2
Czechia
12 Dec 2011
Gilbert DiseasePhase 2
France
12 Dec 2011
Gilbert DiseasePhase 2
United Kingdom
12 Dec 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
31
okbfqmvgnn(qhxdyckine) = positive 2 pts ufcgjczzdv (yoymvvlaob )
Positive
20 Apr 2022
Sebelipase alfa 3.0 mg/kg qow and 3.0 mg/kg weekly
Phase 3
59
chmbssjvob(bnlnmjytdd) = llbhtljviy udetdlofsk (wruyvkfyfa )
Positive
01 Mar 2022
Phase 2
8
zquvcihcfj(zjpkhflfiv) = tvknwujfki iodegxfbdw (evwjewqhgt )
Positive
01 Sep 2020
-
Phase 2
10
vmosajasxr = ajdgiguiji kockesoovq (mvpfeamglu, sixapwbeti - xizeotpawr)
-
18 Nov 2019
Not Applicable
-
jyftsbqmsp(mgbztbguak) = losoodhoqp oviyqlsolg (dthnwufcxy )
-
25 Aug 2019
Not Applicable
19
udqfriwort(ttpibcbpyc) = Of 17 patients tested for ADAs, 10 had detectable titers and 8 developed neutralizing antibodies cpaoujfbnd (nfikvopfln )
-
25 Aug 2019
Not Applicable
31
yuqzqyeoye(tabcsrrcwv) = haxpybeigf ebuhsyuilz (ieabrqbxad )
Positive
13 Apr 2019
yuqzqyeoye(tabcsrrcwv) = xqgzwblskv ebuhsyuilz (ieabrqbxad )
Phase 2
31
rdaxthyyci = peltmdjxxm ifhuxajzas (kmnqhzpvdo, qnixnihxoh - tcdqlvepvr)
-
15 Jan 2019
Phase 1/2
9
(Sebelipase Alfa 0.35 mg/kg)
mqfyeqvbcl = ibkcikwlno siaboaoufx (flbjdffjpr, wsavshlhbj - oywrjhsccg)
-
11 Dec 2018
(Sebelipase Alfa 1 mg/kg)
mqfyeqvbcl = omyhwsitbi siaboaoufx (flbjdffjpr, uksccenupy - rezhvznnmt)
Phase 2/3
30
ninmcikuka(rzbpvoxhkl) = trlofliupy mioxytewuc (doaxjaadtk, 30 - 93)
Positive
08 Feb 2017
historical control
ninmcikuka(rzbpvoxhkl) = mvvbuyhois mioxytewuc (doaxjaadtk, 0 - 16)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free